ERBB2 and breast cancer: In a similar study, Muhammed Murtaza, et al. presented an extensive comparison of biopsy and plasma samples collected from a patient with metastatic ER-positive and HER2-positive breast cancer receiving two lines of targeted therapy over a 3-year clinical course.